CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response [Yahoo! Finance]
CERo Therapeutics Holdings, Inc. (CERO)
Company Research
Source: Yahoo! Finance
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTC PINK: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanisms, announces it will be presenting data on its lead compound CER-1236 at the Society for Immunotherapy of Cancer (SITC) conference being held November 5-9, 2025 in National Harbor, Md. The poster , titled, “CER-1236, an investigational T cell product targeting TIM-4 Ligand, exhibits sustained effector function and resistance to exhaustion,” highlights preclinical data showing the durability of activity for CER-1236. Data demonstrates sustained cell expansion across multiple rounds of antigen stimulation in combination with a robust cytokine response, compared to CD3/CD28 polyclonal stimulation, which induced strong initial activation, but led to cell exhaustion. CERo CEO Chris Ehrlich said, “We believe these data are supportive of what we have see
Show less
Read more
Impact Snapshot
Event Time:
CERO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CERO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CERO alerts
High impacting CERo Therapeutics Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
CERO
News
- CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AMLGlobeNewswire
- CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1) [Yahoo! Finance]Yahoo! Finance
- CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)GlobeNewswire
- CERo Therapeutics Announces Trading on OTCQB MarketGlobeNewswire
- Aggressive cancer warning signs revealed after JFK's granddaughter's diagnosis [FOX News]FOX News
CERO
Sec Filings
- 1/9/26 - Form 4
- 1/9/26 - Form 4
- 1/9/26 - Form 4
- CERO's page on the SEC website